#targeted therapy

A new therapy, BLU-667, shows broad antitumor activity against cancers with a variety of RET alterations.

Results strengthen the path forward for targeted cancer therapies.

How researchers are tweaking engineered immune cells’ cancer-targeting receptors—and why it matters.

Using molecular tests to select the most appropriate treatment leads to better outcomes.

The test will look for mutations that are associated with medical conditions ranging from heart disease to cancer.

Four-drug regimen improves response in people being treated for the first time.

Tafinlar and Mekinist (trametinib approved for a third cancer with specific gene mutation.

Study shows eight-month survival advantage for those not previously treated with chemotherapy.

BLU-667 shrinks thyroid and lung cancers with RET gene alterations.

In three trials larotrectinib shrank tumors in many people whose tumors overexpressed TRK fusion proteins.

Recommendations now include multiple systemic medications in addition to surgery and local therapies.

The life-or-death distinction for melanoma patients

Approval of brentuximab vedotin was based on a study showing improved progression-free survival.

Indication extended to include first-line treatment of HR-positive/HER2-negative advanced or metastatic disease.

“Cancer forces you to get in the fight, to choose the things you really want to do—and do them,” Joan Janssen says.

Lynparza is now indicated for breast cancer patients with BRCA mutations.